Loading…
← CockpitCompetitor Analysis › 600165.SS Ningxia Zhongke Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Ningxia Zhongke Biotechnology Co., Ltd. Class A600165.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Major Diversified
Momentum strong 78
Mkt cap
$679M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$5.43M
20-day average traded
P/B
4.45×
price to book
ROE
-7.3%
delivered
Implied ROE
26.5%
what the price asks
Close · CNYCN¥2.80
1D+0.4%
1W+2.9%
1M-15.2%
3M+20.2%
6M-19.1%
YTD-32.5%
1Y-22.4%
ATR %4.9%
52w lowhigh36.9% off high

What Ningxia Zhongke Biotechnology does

Employees: 904

Ningxia Zhongke Biotechnology at a glance

Size Ningxia Zhongke Biotechnology (600165.SS) is a China Materials company (Chemicals: Major Diversified) with a market value of $679M, the 3138th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.80 on 6 Nov 2026.

Performance Over six months the shares fell 19.1%, against -19.2% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +3.2%); the operating margin is -73.1% (peer median 6.4%).

Valuation It trades at 4.45× book value against a peer median of 2.09× (6th most expensive of 21).

Price implies The share price implies a return on equity of about 26.5%; Ningxia Zhongke Biotechnology delivers -7.3%, so the price asks more than the business earns today.

Relative performance

8010011 May 202611 Aug 20266 Nov 2026600165.SS 83Peer median 80
Six months, rebased to 100: Ningxia Zhongke Biotechnology against the median of its 20 peers (local-currency closes).

Ningxia Zhongke Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥528MCN¥444MCN¥344MCN¥285MCN¥681M
Revenue growth—+29%+21%-58%—
Gross profit-CN¥50.8M-CN¥107M-CN¥79.7M-CN¥111MCN¥64.2M
EBITDA-CN¥260M-CN¥197M-CN¥81.4M-CN¥65.5MCN¥36.4M
Net income-CN¥30.4M-CN¥90.4M-CN¥539M-CN¥466M-CN¥141M
Free cash flow-CN¥702M-CN¥645M-CN¥91.4M-CN¥34.5MCN¥7.95M
Capital expenditureCN¥288MCN¥271MCN¥6.20MCN¥57.7MCN¥59.3M
Total debtCN¥16.4MCN¥860MCN¥677MCN¥1.69BCN¥1.65B

Quarterly statements and history in the cockpit →

Ningxia Zhongke Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%0022743012063001213000826032854189688750300530497530083952346030046882373008016031550006356053664471688669600165.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Ningxia Zhongke Biotechnology is the large dot.

Fundamentals: return on equity against price-to-book

-60%-40%-20%0%20%20×40×60×80×002274301206300121300082603285418930053049753008395234688237300801000635605366688669600165.SSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Ningxia Zhongke Biotechnology is the large dot.

Capital: ROE delivered against the ROE the price implies

-50%0%50%-50%0%50%00227430120630008260328541896887503005305234000635688669600165.SSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Ningxia Zhongke Biotechnology is the large dot.

Ningxia Zhongke Biotechnology competitors and peer comparison

How Ningxia Zhongke Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ningxia Zhongke Biotechnology against its 20 peers (data as of 6 Nov 2026)
Measure600165.SSPeer medianRank in peer set
1-month return-15.2%-14.5%10th lowest of 21
6-month return-19.1%-19.2%11th highest of 21
Return on equity-7.3%4.4%4th lowest of 21
Price / book4.45×2.09×6th most expensive of 21
ROE the price implies26.5%19.5%7th most demanding of 21
ROE delivered-7.3%4.3%4th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Ningxia Zhongke Biotechnology 600165.SSChina$679M-19%+8%-7%4.45×26.5%-7.3%
Jiansu Huachang Chemical 002274.SZChina$679M-25%+9%-3%0.87×7.4%-3.3%
Shandong Sanyuan Biotechnology 301206.SZChina$676M-18%+15%2%1.07×8.4%1.8%
Shandong Yanggu Huatai Chemical 300121.SZChina$648M-20%+11%4%1.17×11.1%4.4%
Liaoning Oxiranchem,Inc 300082.SZChina$716M-39%+4%4%1.69×17.6%3.8%
Shandong Jianbang New Material 603285.SSChina$631M-40%+8%8%2.39×24.6%7.9%
KH Neochem 4189.TJapan$732M+20%-11%13%1.55×8.0%12.8%
Hunan Xiangtou Goldsky Titanium Industry Technology 688750.SSChina$629M-27%+4%4%2.49×29.4%3.6%
Hunan Lead Power Technology 300530.SZChina$621M+2%+16%-58%54.64×460.5%-57.5%
JCU 4975.TJapan$759M-26%+2%18%2.14×22.0%17.6%
Ningbo Bohui Chemical Technology 300839.SZChina$606M-4%+42%8%4.93×32.3%8.5%
Daxin Materials 5234.TWTaiwan$767M-42%+10%27%7.65×62.8%26.7%
Zhejiang Dragon Technology 603004.SSChina$597M-18%-11%5%1.89×19.8%4.8%
Hubei Chaozhuo Aviation Technology 688237.SSChina$776M+6%-1%1%4.26×24.5%1.0%
Shandong Taihe Technologies 300801.SZChina$589M-41%-2%5%1.46×15.4%5.2%
Xinyaqiang Silicon Chemistry 603155.SSChina$788M-6%+6%4%2.34×19.2%4.3%
China Catalyst 688267.SSChina$578M-27%-3%5%1.34×10.3%4.8%
Ningxia Yinglite Chemicals 000635.SZChina$562M+17%-14%-62%4.64×33.0%-62.2%
Jiangxi Hungpai New Material 605366.SSChina$821M-47%+2%-6%2.04×18.9%-6.3%
Sanyo Chemical Industries 4471.TJapan$823M+24%0%7%0.80×6.6%7.4%
Polyrocks Chemical 688669.SSChina$831M+40%-8%-27%5.55×64.8%-27.2%

Questions

Which companies are Ningxia Zhongke Biotechnology's closest peers?
The cockpit's peer set: Jiansu Huachang Chemical (002274.SZ), Shandong Sanyuan Biotechnology (301206.SZ), Shandong Yanggu Huatai Chemical (300121.SZ), Liaoning Oxiranchem,Inc (300082.SZ), Shandong Jianbang New Material (603285.SS), KH Neochem (4189.T), Hunan Xiangtou Goldsky Titanium Industry Technology (688750.SS), Hunan Lead Power Technology (300530.SZ).
Is Ningxia Zhongke Biotechnology expensive compared with its peers?
On price / book it trades at 4.45× against a peer median of 2.09×, 6th most expensive of 21 in its peer set. The share price implies a return on equity of about 26.5%; Ningxia Zhongke Biotechnology delivers -7.3%, so the price asks more than the business earns today.
How has Ningxia Zhongke Biotechnology stock performed?
Over six months to 6 Nov 2026 the shares returned -19.1% against -19.2% for the median peer; over one year -22.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.